Abstract:
This invention concerns compounds of formula including the stereoisomers and the pharmaceutically acceptable acid addition salt forms thereof, wherein R is C alkyl, NR R , OR or SR ; R is hydrogen, C alkyl, C alkyloxy or C alkylthio; R is Ar or Het ; R and R are each independently selected from hydrogen, halo, C alkyl, C alkyloxy, trifluoromethyl, cyano, nitro, amino, and mono- or di(C alkyl)amino; R is hydrogen, C alkyl, C alkylsulfonyl, C alkylsulfoxy or C alkylthio; R is hydrogen, C alkyl, mono- or di(C cycloalkyl)methyl, C cycloalkyl, C alkenyl, hydroxyC alkyl, C alkylcarbonyloxy-C alkyl or C alkyloxyC alkyl; R is C alkyl, mono- or di(C cycloalkyl)-methyl, Ar CH , C alkyloxyC alkyl, hydroxyC alkyl, C alkenyl, thienylmethyl, furanylmethyl, C alkylthioC alkyl, mono- or di(C alkyl)aminoC alkyl, di(C alkyl)amino, C alkylcarbonylC alkyl; or R and R taken together with the nitrogen atom to which they are attached may form a pyrrolidinyl, piperidinyl, homopiperidinyl or morpholinyl group, optionally substituted with C alkyl or C alkyloxyC alkyl; and Ar and Ar are each optionally substituted phenyl; and Het is optionally substituted pyridinyl; having CRF receptor antagonistic properties; pharmaceutical compositions containing such compounds as active ingredients; methods of treating disorders related to hypersecretion of CRF such as depression, anxiety, substance abuse, by administering an effective amount of a compound of formula (I).